A bureaucrat who said no to everything rarely got in trouble." - Tom Clancy, Executive Orders
Today, we take a look at a small 'Tier 4' biotech concern that saw several insiders buy shares in December. The insider purchases immediately follow trial results that triggered a decent sell-off in the stock. The company has an early stage but a diverse and intriguing pipeline. A full investment analysis is presented in the paragraphs below.
Protagonist Therapeutics (PTGX) is a Newark, California based clinical-stage biopharmaceutical company that IPO'd in 2016. The company's product candidates derive from their proprietary peptide technology platform. The pipeline is segregated into two categories: blood disorders and IBD. Overall, the pipeline is quite young with the two most advanced candidates being PTG-300 and PTG-200. The youngest asset, currently in clinical development, is PN-943, which is an a4b7 integrin antagonist in development for ulcerative colitis. Protagonist Therapeutics, currently, has a market capitalization of roughly $190 million and trades for around $7.00 a share.
There was an uptick of insider buying in the stock last month. On December 3rd, Bryan Giraudo, Director, bought 8,000 shares at an average price of $5.70 a share; Suneel Gupta, EVP Clinical Operations, bought 30,000 shares at an average price of $5.13 a share; Dinesh Patel, President and Chief Executive Officer, bought 30,000 shares at an average price of $5.62 a share; and, finally, Donald Kalkofen, Chief Financial Officer, bought 1,175 shares at an average price of $5.10 a share. It should be noted that this is the first insider buying in this name since May of 2017.
Source: Company Presentation
PTG-300 is an injectable hepcidin mimetic peptide in development to treat iron overload anemia and related rare blood diseases: -Thalassemia, polycythemia vera, hereditary hemochromatosis, and myelodysplastic syndrome. Hepcidin is a key hormone regulating iron homeostasis. The FDA and EU authorities have granted the drug Orphan Drug and Rare Disease status, and the FDA has also granted Fast Track designation for the treatment of patients with Thalassemia. Earlier this week, the company initiated a Phase 2 clinical trial evaluating hepcidin mimetic PTG-300 in patients with hemochromatosis.
Source: Company Presentation
The most advanced indication is -Thalassemia. -Thalassemia is a rare genetic blood disorder that causes impaired red blood cell production that leads to potentially fatal chronic anemia. -Thalassemia is caused by mutations in the HBB gene. The gene possesses instructions for making beta-globin, a key part of hemoglobin. -Thalassemia is classified into two subtypes: transfusion-dependent thalassemia and non-transfusion dependent thalassemia. The disorder is most common in people that hail from the Mediterranean, the Arabian Peninsula, Southeast Asia, and southern China. Approximately 300,000 people are affected worldwide. In 2018, Decision Resource Group reported that the prevalence in the US is extremely low with an estimated 3,000 people and approximately 300 patients are born each year with the disease.
Source: Company Presentation
The big opportunity is for a more effective treatment for chronic anemia to decrease the frequency of blood transfusions. Regular and lifelong blood transfusions commonly lead to iron overload in target organs such as the heart and liver. Decreased number of transfusions also means easier disease management and potential cost savings.
Source: Company Presentation
On December 3rd, the company announced preliminary data from their Phase 2 clinical trial, TRANSCEND, evaluating PTG-300 in patients with transfusion-dependent beta-thalassemia. The trial is a global single-arm, open-label, multiple-ascending dose design that will evaluate safety and efficacy. The data showed dose-related drug exposure and reductions in serum iron and transferrin saturation levels from baseline for the 40 mg and 80 mg weekly doses. However, the results are too preliminary to get excited. The steep decline in shares post announcement is being blamed on the expectation that the company would be announcing definitive results and not preliminary data. Additional data, such as longer follow-up periods and additional dosing regimens is expected in 2020. The company is planning on launching a Phase 2 trial in patients with hereditary hemochromatosis and an investigator-sponsored study of PTG-300 in patients with myelodysplastic syndromes by early 2020.
PTG-200 is an oral Interleukin-23 receptor antagonist being developed initially for moderate-to-severely active Crohn's disease. The drug has completed a Phase 1 trial thus far. In 2017, Protagonist Therapeutics entered into a collaboration agreement with Janssen for a worldwide license to co-develop and commercialize PTG-200 for all indications including inflammatory bowel disease. In 2016, GlobalData estimated that Crohn's disease market reached approximately $9.6 billion across seven major markets: United States, France, Germany, Italy, Spain, United Kingdom, and Japan. Furthermore, the market is expected to grow approximately 3.7% per year to $13.84 billion by 2026.
Source: Company Presentation
The current tumor necrosis factor-alpha antibody drugs that dominate the market for moderate-to-severe IBD are Humira and Remicade, which are both injectable. Roughly, one-third of IBD patients do not respond to TNF- antibody drugs and roughly 30% to 40% become refractory within the first year of treatment. Furthermore, TNF- antibody drugs may predispose patients to an increased risk of serious infection and the development of anti-drug antibodies, which over time can weaken the drug response. Oral GI-restricted peptide drugs like PTG-200 can improve convenience, safety, tolerability, and compliance.
The first patient has been dosed in the Phase 2 study of PTG-200 in patients with moderate to severe Crohn's disease. Results from the trial are expected to be released in 2021.
Source: Company Presentation
Analyst Commentary and Balance Sheet
As of September 30, 2019, the company had cash, cash equivalents, and marketable securities of roughly $140 million. Research and development expenses for the third quarter were $17.2 million, compared to $12.1 million in Q3 of 2018. General and administrative expenses for the quarter were $4 million compared to $3.3 million in Q3 of the prior year. Licensing and collaboration revenue came in at $4.1 million for the quarter, which is down roughly 30% year-over-year. Overall, the company had a net loss of $16.4 million in the quarter compared to a net loss of $8.7 million in the same period of last year. Back in October, the company filed a preliminary prospectus for a $250 million mixed shelf offering. Then, on November 27th, the company filed to offer $75 million worth of common stock. The company also picked up a $5 million milestone payout from Janssen earlier this week.
The company is sparsely covered on the Street with only three analyst firms covering it that I can find. On December 7th, the analyst at Nomura said he's an aggressive buyer of shares following the steep selloff. He stated that the data are misunderstood and that, "the Transcend Phase 2 open-label study suggests that PTG-300 is effective at reducing serum iron levels even in patients with significantly elevated iron levels at baseline". Nomura's buy rating and $29 price target stands. On August 13th, SVB Leerink reiterated their outperform rating. On August 2nd, H.C. Wainwright placed a buy rating on the stock and set a price target of $23 a share.
There is a lot to like about this small developmental company. It has multiple 'shots on goal', is aiming at some lucrative parts of the disease market, and has its first insider buying in some time. However, Protagonist still has an early-stage pipeline. The most likely time frame for any Phase 3 development to commence is probably in 2021.
No options are available right now against the equity, so a buy-write option strategy to establish an initial position is not available. I have picked up a few hundred shares in PTGX as it would seem worthy of a very small 'watch item' holding for the time being. The shares have seen support just under current trading levels so far in its history as a public company as well.
I also want to keep an eye on PTGX to watch how its pipeline develops. I offer up this analysis for others who might want to do the same.
The most natural action of a senior official is to breed junior officials." - Jason Jennings
Bret Jensen is the Founder of and authors articles for the Biotech Forum, Busted IPO Forum, and Insiders Forum
January Sale! Just send us a message with the title '33% Off' and we will send you a special promo link to activate a risk-free two-week trial AND one third off your first year of membership into The Insiders Forum. Peruse our market-beating model portfolio, access our investment archives and join us on Live Chat every trading day. What do you have to lose? But don't hesitate too long. Our model portfolio has crushed that of the Russell 2000 (67.98% versus 36.99% as of 01/10/2020) since its launch
Disclosure: I am/we are long PTGX. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Additional disclosure: I have a small watch item position in PTGX at this time
Here is the original post:
Kicking The Tires On Protagonist Therapeutics - Seeking Alpha
- Updated Guidance on Ulcerative Colitis Management - Physician's Weekly - January 14th, 2020
- Gut Inflammation Linked to the Development of Parkinson Disease - Psychiatry Advisor - January 14th, 2020
- Will Theravance Biopharma Finally Break Out in 2020? - The Motley Fool - January 14th, 2020
- AbbVie And Allergan Merger, And Other News: The Good, Bad And Ugly Of Biopharma - Seeking Alpha - January 14th, 2020
- OSE Immunotherapeutics Announces Issuance of a New Patent in Japan for Tedopi on Inducing Early T-Lymphocyte Memory Response - Yahoo Finance - January 14th, 2020
- Lerner and Rowe Honor the Memory of Dana Marshall-Bernstein by Supporting the Crohn's and Colitis Foundation's Inaugural Courage Ball - PR Web - January 14th, 2020
- Phase 1 Ulcerative Colitis Trial of Brilacidin Approved by UK Regulators - IBD News Today - January 11th, 2020
- IBD Tied to Adverse Pregnancy Outcomes - MedPage Today - January 11th, 2020
- Higher Risk of GI Events During Immunotherapy for Patients With IBD - Cancer Therapy Advisor - January 11th, 2020
- US House passes bill regulating PFAS; Dan Bishop, Mark Meadows among the no votes - The Progressive Pulse - January 11th, 2020
- A Lasting Legacy: DuPont, C8 Contamination and the Community Left to Grapple With the Consequences - alleghenyfront.org - January 11th, 2020
- Innovation Wellness opens in Eaton - Register-Herald - January 11th, 2020
- Ulcerative Colitis Market 2019 Industry Outline, Global Executive Players, Interpretation and Benefit Growth to 2025 - BulletintheNews - January 11th, 2020
- 2020 Ulcerative Colitis Market Report Share, Types, Region and Overview 2025 - Instanews247 - January 11th, 2020
- Sorrento Announces Filing for Approval of Infliximab Biobetter Antibody by Its Partner Mabpharm in China - Yahoo Finance - January 11th, 2020
- Ulcerative Colitis Market Projected to Exhibit a High Single-Digit CAGR through 2026 - Food & Beverage Herald - January 11th, 2020
- Mabpharm Seeks Approval of Infliximab Biobetter in China - Ankylosing Spondylitis News - January 11th, 2020
- Xeljanz XR Approved for Ulcerative Colitis - Monthly Prescribing Reference - December 19th, 2019
- With More Healthcare in IBD Comes Better Outcomes - MedPage Today - December 19th, 2019
- For Ulcerative Colitis, Extended-Release Xeljanz XR Approved by FDA - IBD News Today - December 19th, 2019
- Weight Loss and Parkinson's Disease - Parkinson's News Today - December 19th, 2019
- Seven Practice-Changing Studies You Need to Know: ACG 2019 - Medscape - December 19th, 2019
- FDA Approves XELJANZ XR (tofacitinib) Extended-Release Tablets for the Treatment of Ulcerative Colitis - Business Wire - December 19th, 2019
- Spinathon raises money to fight Crohn's and colitis - New Jersey Hills - December 19th, 2019
- Nourish Your Health podcast with Tyler Lafleur with HPHI: Inflammatory food and drinks, inadequate rest, stress can damage your intestines - The... - December 19th, 2019
- IBD Patients and Pregnancy: A Balancing Act - MedPage Today - December 19th, 2019
- Exploradio: Cleveland Researchers Look for New Ways to Treat the Incurable Crohn's Disease - WKSU News - December 19th, 2019
- 'Dark Waters': Behind-the-Scenes With Attorney Who Took on DuPont - MedPage Today - December 19th, 2019
- Rotation renovation: A look at the Rangers' projected starters following the addition of Corey Kluber - The Dallas Morning News - December 19th, 2019
- Ulcerative Colitis Market to Grow with a High CAGR Global Analysis, Key Players, Trends, Size and Forecast by 2025 - Market Research Sheets - December 19th, 2019
- Is AbbVies Dividend Capable Of Long-Term Growth? - The Motley Fool - December 19th, 2019
- EASTERN NIAGARA HEALTHLINES: All about infusion therapy | Lifestyles - Lockport Union-Sun & Journal - December 19th, 2019
- 8 Wonder Foods that Can Improve the Health of Many Students - University Herald - December 19th, 2019
- Capital Digestive Care Taps 3 GIs for Maryland Locations - GlobeNewswire - November 25th, 2019
- Halifax doctor seeks poop samples in the name of research - CBC.ca - November 25th, 2019
- When To Take Probiotics - The Best Time To Take Probiotics - Women's Health - November 25th, 2019
- What causes you to fart more than usual and the signs it's something more serious - Mirror Online - November 25th, 2019
- Rome suing over thirty companies in water pollution lawsuit - MDJOnline.com - November 25th, 2019
- Abivax Receives French Regulatory Authority (ANSM) Approval to Include French Study Sites in its Phase 2b Ulcerative Colitis Clinical Trial and... - November 21st, 2019
- Inflammatory Bowel Disease Insight Report: Current Therapies, Drug Pipeline and Outlook - BioSpace - November 21st, 2019
- Pfizers Xeljanz In the Crowded Rheumatoid Drugs Market - Forbes - November 21st, 2019
- Thetis Pharmaceuticals Receives Funding from the Crohn's & Colitis Foundation to Support Investigational Mucosal Healing Therapy for Inflammatory... - November 21st, 2019
- Global Ulcerative Colitis Market by Types, Applications, Countries, Companies and Forecasts to 2024 covered in a Latest Research - Editorials 360 - November 21st, 2019
- How Can I Tell the Difference Between Irritable Bowel Syndrome and Colorectal Cancer? - Dana-Farber Cancer Institute - November 21st, 2019
- Global Ulcerative Colitis Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2025 - The Industry Press Releases - November 21st, 2019
- Global Ulcerative Colitis Treatment Market 2020 Expected To Witness A Sustainable Growth Over 2029:- Cipla Limited, Bayer pharmaceuticals Corp and... - November 21st, 2019
- Palatin Presents On Pl8177 Oral Colon Delivery Formulation For Ulcerative Colitis At The 7Th CPC Symposium On Peptide Therapeutics - PRNewswire - October 17th, 2019
- Reading the Fine Print: Discovering I Have Ulcerative Colitis | - IBD News Today - October 17th, 2019
- Severance researchers find intestinal inflammatory inhibition gene - Korea Biomedical Review - October 17th, 2019
- Food giant Nestle pivots to gain a foothold in the personal nutrition market - CNBC - October 17th, 2019
- Ulcerative Colitis Market Size, Forthcoming Developments, Business Opportunities, Market Upside and Future Investments 2019-2024 - Joliet Observer - October 17th, 2019
- Who will stick and who won't for the Twins in 2020? - Star Tribune - October 17th, 2019
- How an IU senior turned her struggle with chronic illness into an effort to help others - IndyStar - October 15th, 2019
- Ulcerative Colitis Market to See Massive Growth by 2026 With Top Companies AstraZeneca, Merck & Co., Inc., InDex Pharmaceuticals Holding AB,... - October 15th, 2019
- AbbVie, Gilead and Allergan 3-peat with September's top pharma TV spending - FiercePharma - October 15th, 2019
- Was It the Hummus or the Familiarity? - The New York Times - October 15th, 2019
- Ulcerative Colitis Drugs Market Outlook : Business Overview, Industry Insights, Upcoming Trends and Top Company Analysis Forecast by 2026 - Connecting... - October 15th, 2019
- Is There a Best Time to Take Probiotics? - Healthline - October 15th, 2019
- Kate Farms Releases First Study Demonstrating Pediatric Weight Gain and Improved Tolerance on Plant-Based Enteral Formula - PRNewswire - October 15th, 2019
- Charity Walk to Help People Affected by Crohn's, Ulcerative Colitis - Reston Now - September 23rd, 2019
- 1st Clinical Trial of Potential Ulcerative Colitis Treatment, Oral Brilacidin, in Planning Phase - IBD News Today - September 23rd, 2019
- Walkers 'Take Steps' to find a cure for Crohn's and Colitis - WKTV - September 23rd, 2019
- Living with Crohns disease: Kristophers story - WPMT FOX 43 - September 23rd, 2019
- THOMA COLUMN| The Gibson Gap: Twins have a hole in their pitching staff - Mankato Free Press - September 23rd, 2019
- The Link Between Inflammatory Bowel Disease and Depression - Medical Bag - September 23rd, 2019
- Minnesota Twins Starter Kyle Gibson Has Battled Illness for Most of the Season - Zone Coverage - September 23rd, 2019
- Ulcerative Colitis Therapeutics Market Growth, Industry Size, Share, Market Status Analysis and Demand - NewsStoner - September 23rd, 2019
- Ulcerative Colitis Treatment Market Manufacturing Cost Study with Latest Trends & Dynamics By 2028 - Marketing Analytics - September 23rd, 2019
- Home Depot to phase out products containing chemical linked to cancer and serious health issues - KYW Newsradio 1060 - September 23rd, 2019
- The Real Story Behind Dark Waters - Film School Rejects - September 23rd, 2019
- Better Buy: Vertex Pharmaceuticals vs. Galapagos - The Motley Fool - September 23rd, 2019
- Ulcerative Colitis Immunology Drugs Market Set for Rapid Growth And Trend, by 2025 - Spaceflight News - September 23rd, 2019
- Immutep to receive $7.4m from GSK - 7NEWS - September 23rd, 2019
- TV personality Dr. Oz is now on the board of a biotech company - STAT - September 23rd, 2019
- The Japanese Diet: Benefits, Food List, and Meal Plan - Healthline - September 23rd, 2019
- Stafford woman got 'sicker and sicker' after having breast implants - Fredericksburg.com - September 23rd, 2019
- Everything You Need to Know About Ulcerative Colitis - April 22nd, 2019
- 6 Ways to Naturally Treat Ulcerative Colitis | Everyday Health - April 22nd, 2019
- Colitis Causes, Types, Treatment, Symptoms & Diet - April 22nd, 2019
- Medical Marijuana for Ulcerative Colitis | Marijuana Doctors - February 23rd, 2019